Steven Snapinn

发表

Assessment of futility in clinical trials

Steven Snapinn, Mon-Gy Chen, Qi Jiang, 2006, Pharmaceutical statistics.

Predicting analysis time in event-driven clinical trials with event-reporting lag.

Steven Snapinn, Qi Jiang, Jianming Wang, 2012, Statistics in medicine.

Analysis of Safety Data

Steven Snapinn, Qi Jiang, 2016 .

Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials

Steven Snapinn, Qi Jiang, Haijun Ma, 2015, Therapeutic innovation & regulatory science.

Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation

Steven Snapinn, Qi Jiang, Chunlei Ke, 2015, Therapeutic innovation & regulatory science.

Controlling the type 1 error rate in non‐inferiority trials

Steven Snapinn, Qi Jiang, Qi Jiang, 2008, Statistics in medicine.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Steven Snapinn, Ulf de Faire, Richard B Devereux, 2002, The Lancet.

Choice of Metrics and Other Considerations for Benefit–Risk Analysis in Subgroups

Steven Snapinn, Qi Jiang, 2017 .

Indirect comparisons in the comparative efficacy and non‐inferiority settings

Steven Snapinn, Qi Jiang, Qi Jiang, 2011, Pharmaceutical statistics.